Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral Baricitinib Performs Well in Phase 3 for Atopic Dermatitis

Key clinical point: The Janus kinase 1/2 inhibitor baricitinib shows promise as a novel oral treatment for moderate or severe atopic dermatitis.

Major finding: Among atopic dermatitis patients on concomitant topical corticosteroids, a 75% improvement on Eczema Area and Severity Index at 16 weeks was achieved in 48% of those on baricitinib at 4 mg/day, 43% with baricitinib at 2 mg/day, and 23% on placebo.

Study details: BREEZE-AD7 was a phase 3, multicenter, 16-week, double-blind, three-arm study including 329 adults with moderate or severe atopic dermatitis.

Disclosures: The BREEZE-AD7 study was sponsored by Eli Lilly. The presenter reported serving as an adviser to, paid speaker for, and/or recipient of research grants from that pharmaceutical company and more than two dozen others.

Citation:

Reich K. EADV Congress, late breaker.